![]() | ||
AGENDA | ||
. | ||
12:30 – 1:30 | Registration & Networking | |
1:30 – 1:40 | Welcome and Opening Remarks Phil Greenberg, Head of the Program in Immunology and member of the Clinical Research Division, Fred Hutch; Professor of Medicine/Oncology and of Immunology, University of Washington Jim Edwards, Publisher, Xconomy | |
1:40 – 2:10 | Can CAR-T Be Tamed? Hans Bishop, CEO, Juno Therapeutics Richard Maziarz, Medical Director, Adult Blood and Marrow Stem Cell Transplant Program, Oregon Health and Science University Alex Lash, National Biotechnology Editor, Xconomy (moderator) | |
2:10 – 2:40 | Chasing Cancer Vaccines Andrew Allen, CEO, Gritstone Oncology Jay Venkatesan, President, Alpine Immune Sciences Alex Lash, National Biotechnology Editor, Xconomy (moderator) | |
2:40 – 3:10 | Teaming Up On Immunotherapy’s Frontier Jill O’Donnell-Tormey, CEO, Cancer Research Institute Ilya Shmulevich, Professor, Institute for Systems Biology Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Company Andrew Albertson, Partner, Fenwick & West (moderator) | |
3:10 – 3:40 | Networking Break | |
3:40– 4:05 | Kids, Cancer Care, and Lessons Learned Michael Jensen, MD, Director, Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute | |
4:05 – 4:35 | Deciphering The Immune System Brad Gray, CEO, NanoString Technologies Chad Robins, President & CEO, Adaptive Biotechnologies Alex Lash, National Biotechnology Editor, Xconomy (moderator) | |
4:35 – 5:05 | T Cell Treatments Under The Radar Maria Fardis, CEO, Lion Biotechnologies Sylvia Lee, Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center | |
5:05 – 5:30 | How Lung Cancer Became Immunotherapy’s Biggest Success Renato Martins, Medical Director, Thoracic/Head and Neck Oncology, University of Washington School of Medicine | |
5:30 – 6:30 | Networking Reception |
*Schedule is subject to change.